 NEW YORK, Dec. 05, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, announced preliminary results from Cellectis dose escalation Phase 1 BALLI-01 study of UCART22 product candidate in relapsedrefractory B-cell Acute Lymphoblastic Leukemia B-ALL were presented at the American Society of Hematology ASH Annual Meeting. This is the first publicly released data from Cellectis BALLI-01 clinical trial. 